List of Excipients in Branded Drug STAVUDINE

« Back to Dashboard

Generic Drugs Containing STAVUDINE

Company	Ingredient	NDC	Excipient
Cipla Ltd	stavudine	53104-0111	CARBOXYMETHYLCELLULOSE SODIUM
Cipla Ltd	stavudine	53104-0111	MANNITOL
Cipla Ltd	stavudine	53104-0111	METHYLPARABEN
Cipla Ltd	stavudine	53104-0111	PROPYLPARABEN
Cipla Ltd	stavudine	53104-0111	SACCHARIN SODIUM

What are the Most Frequently-Used Excipients in STAVUDINE?

# Of NDCs	Excipient
3	ANHYDROUS LACTOSE
1	CARBOXYMETHYLCELLULOSE SODIUM
3	CELLULOSE, MICROCRYSTALLINE
1	D&C RED NO. 28
1	FD&C BLUE NO. 1

Stavudine Excipient Strategy and Commercial Opportunities in Generic HIV Pharmaceuticals

Last updated: September 7, 2026

Stavudine, or d4T, is an older nucleoside reverse transcriptase inhibitor with limited current commercial potential because of mitochondrial toxicity, peripheral neuropathy, lipoatrophy, lactic acidosis, and the availability of safer antiretroviral agents. The strongest remaining opportunities are low-cost pediatric formulations, replacement products for legacy treatment programs, and geographically targeted fixed-dose combinations. New excipient patents or premium reformulations have weak commercial prospects unless they solve stability, taste, dosing, or supply-chain problems at materially lower cost.

What is the current regulatory status of stavudine?

Stavudine was approved by the U.S. Food and Drug Administration under the brand Zerit for treatment of HIV-1 infection in combination with other antiretroviral agents. The original dosage forms included hard gelatin capsules and an oral solution powder for reconstitution, with capsule strengths of 15 mg, 20 mg, 30 mg, and 40 mg [1].

The FDA-approved product is no longer a mainstream commercial HIV therapy. U.S. HIV treatment guidelines recommend integrase inhibitor-based regimens rather than stavudine-containing therapy, and the National Institutes of Health describes stavudine as an older drug with substantial toxicity concerns [2].

Regulatory issue	Stavudine position
Active ingredient	Stavudine, d4T
Drug class	Thymidine nucleoside reverse transcriptase inhibitor
Original U.S. brand	Zerit
Original sponsor	Bristol-Myers Squibb
U.S. dosage forms	Capsules and powder for oral solution
Current treatment role	Limited or obsolete in routine first-line therapy
Biosimilar pathway	Not applicable; stavudine is a small molecule
Generic pathway	Abbreviated New Drug Application, subject to product availability and reference-drug requirements
Orange Book relevance	Historical product and patent information; no meaningful current innovator exclusivity moat
Commercial status	Primarily a low-cost, legacy-market opportunity

When did stavudine lose exclusivity?

Stavudine’s principal composition and product exclusivity periods expired years ago. The original U.S. approval dates to the 1990s, so any ordinary 20-year patent term associated with the original active ingredient or early product development has ended. No current commercial opportunity depends on extending the original Zerit exclusivity position.

The relevant barriers are now regulatory, manufacturing, market-access, and clinical rather than basic molecule patent rights.

What patents protect stavudine?

The commercially important patent categories historically associated with stavudine included:

1. The stavudine active ingredient and chemical synthesis.
2. Pharmaceutical compositions containing stavudine.
3. Oral dosage forms, including capsules and liquid preparations.
4. Methods of treating HIV infection with stavudine.
5. Combinations with other antiretroviral agents.

Those patent categories do not create a meaningful current barrier to generic development. Method-of-use claims directed to treating HIV with stavudine are also commercially weak because current clinical practice has moved away from stavudine.

The most relevant modern intellectual-property opportunities would involve a genuinely differentiated formulation, such as a heat-stable pediatric dosage form, a long-acting delivery system, or a technically difficult fixed-dose combination. Even those claims would face obviousness, written-description, enablement, and limited-market challenges.

What excipients were used in stavudine products?

The original capsule formulation used conventional immediate-release excipients. FDA labeling identified inactive ingredients including lactose, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate. The capsule shell contained gelatin, titanium dioxide, and colorants [1].

The oral solution powder used a different excipient system designed for reconstitution, palatability, preservation, and suspension control. The label identified sucrose, sodium carboxymethylcellulose, methylparaben, propylparaben, and flavoring components [1].

Dosage form	Functional excipient requirements	Historical excipient approach
Immediate-release capsule	Dilution, flow, disintegration, lubrication	Lactose, microcrystalline cellulose, sodium starch glycolate, magnesium stearate
Powder for oral solution	Sweetness, viscosity, preservation, redispersibility	Sucrose, sodium carboxymethylcellulose, methylparaben, propylparaben, flavor
Pediatric liquid	Dose uniformity, palatability, microbial control	Preserved aqueous suspension or solution
Fixed-dose combination tablet	Compatibility among multiple actives, compression, dissolution	Direct compression or wet granulation with conventional fillers and disintegrants

The original formulation is commercially useful as a benchmark, but it should not be copied without confirming the current reference formulation, manufacturing process, impurity profile, and regulatory requirements in the target jurisdiction.

Which excipient strategy is strongest for a generic stavudine product?

The strongest strategy is a simple, low-cost immediate-release capsule or tablet with a robust dissolution profile and minimal manufacturing complexity.

Immediate-release capsule strategy

A generic capsule can use a conventional blend of:

• Microcrystalline cellulose or dibasic calcium phosphate as filler
• Sodium starch glycolate or croscarmellose sodium as disintegrant
• Colloidal silicon dioxide as glidant
• Magnesium stearate or sodium stearyl fumarate as lubricant
• Hard gelatin or hydroxypropyl methylcellulose capsule shells

Microcrystalline cellulose is attractive for low-dose uniformity and direct compression. Dibasic calcium phosphate can reduce moisture sensitivity but may create compatibility or density differences in low-dose blends. Magnesium stearate is economical but requires lubrication control because excessive blending can reduce dissolution.

Pediatric oral formulation strategy

A pediatric formulation is the more credible excipient opportunity. A 1 mg/mL oral solution or suspension must address:

• Taste masking
• Dose uniformity after storage and shaking
• Preservative effectiveness
• Reconstitution water quality
• Stability under hot and humid conditions
• Syringe-based dosing
• Container-closure compatibility
• Pediatric excipient safety

Sucrose provides effective taste masking but increases the risk of microbial growth, dental concerns, and use limitations in certain patient populations. Sorbitol or xylitol can reduce sucrose dependence but may cause gastrointestinal effects at higher doses. A non-sugar system using sucralose or a combination of high-intensity sweeteners may improve product positioning, but flavor acceptability must be confirmed in pediatric testing.

Sodium carboxymethylcellulose can control sedimentation and improve redispersibility in a suspension. Xanthan gum or hydroxypropyl cellulose may provide alternative rheology, but excessive viscosity can impair dosing through oral syringes.

Methylparaben and propylparaben are established preservatives, but many modern pediatric products seek alternatives because of regulatory, labeling, or market-preference concerns. Potassium sorbate, sodium benzoate, or preservative-free single-dose packaging may provide differentiated options, subject to pH and microbial challenge testing.

What formulation patents could protect a new stavudine product?

A new formulation patent would need to claim a technical result that is difficult to obtain using routine excipient selection. The most defensible claim themes would include:

1. A specific polymer and sweetener system that improves taste without reducing dissolution.
2. A stable, low-viscosity pediatric suspension with defined particle-size distribution.
3. A moisture-resistant solid dosage form for tropical climates.
4. A preservative system that maintains microbiological quality across the labeled in-use period.
5. A fixed-dose combination with demonstrated chemical compatibility and dissolution performance.
6. A multiparticulate or dispersible dosage form with improved dose flexibility.
7. A manufacturing process that limits degradation products or polymorphic conversion.

A patent that merely substitutes one conventional filler for another would likely have limited strength. The claim should connect composition to measurable performance, such as stability at 40°C/75% relative humidity, reduced degradation, improved redispersibility, or clinically meaningful dosing accuracy.

How strong is the patent estate for stavudine?

The legacy stavudine patent estate is weak from a current commercial perspective.

Patent category	Current commercial strength
Active pharmaceutical ingredient	Low; historical protection expired
Basic oral capsule	Low; conventional formulation
Oral solution	Low to moderate only if a specific active formulation claim remains enforceable, which is unlikely for the original product
HIV treatment method	Low because of clinical displacement
Fixed-dose combination	Product-specific; dependent on the other active ingredients
Manufacturing process	Potentially relevant if process economics or impurity control are difficult
New pediatric formulation	Moderate if supported by unexpected stability or palatability data
Long-acting delivery system	Technically possible but commercially weak given the drug’s toxicity profile

An investor or generic manufacturer should treat regulatory exclusivity and patent exclusivity as largely absent. The investment case depends on production cost, procurement access, geographic demand, and the ability to supply markets where older antiretroviral products remain in use.

What generic entry risks exist for stavudine?

Generic entry is technically straightforward for a conventional capsule. The main risks are commercial rather than patent-based.

Regulatory risks

A sponsor may need to demonstrate pharmaceutical equivalence, bioequivalence, content uniformity, dissolution, stability, and impurity control. For an oral solution or suspension, the formulation must also establish microbiological quality, preservative effectiveness, in-use stability, and accurate dosing.

A product intended for low- and middle-income markets may follow national registration procedures, World Health Organization prequalification requirements, or procurement-agency standards rather than a U.S. ANDA pathway.

Clinical and market risks

Stavudine is associated with dose-related and cumulative toxicity. The FDA label warns about peripheral neuropathy, pancreatitis, lactic acidosis, hepatic steatosis, and lipoatrophy [1]. These risks limit physician demand and make substitution into modern treatment guidelines unlikely.

The commercial market is therefore concentrated in:

• Legacy treatment programs
• Salvage settings where alternatives are unavailable
• Certain national tenders
• Emergency or humanitarian procurement
• Research or reference-use markets

Which companies are challenging or replacing stavudine?

The principal competitive threat does not come from another stavudine generic. It comes from newer antiretroviral regimens.

Modern treatment programs generally favor dolutegravir-based combinations, often with tenofovir and lamivudine or emtricitabine. Tenofovir disoproxil fumarate, tenofovir alafenamide, abacavir, lamivudine, emtricitabine, and integrase inhibitors have displaced stavudine across most treatment settings [2,3].

Generic manufacturers in India, South Africa, China, and other production centers have supplied low-cost alternatives to legacy antiretrovirals. The competitive comparison is therefore based on regimen value rather than molecule-to-molecule differentiation.

Product characteristic	Stavudine	Modern alternatives
Toxicity profile	Unfavorable	Generally improved
Dosing flexibility	Available in pediatric and capsule forms	Broad range of fixed-dose products
Manufacturing cost	Low	Low for mature generics
Guideline support	Limited	Stronger
New formulation potential	Technically available	Commercially more attractive
Procurement demand	Declining and localized	Broad and sustained

What are the commercial opportunities for stavudine excipients?

Low-cost pediatric supply

A heat-stable pediatric formulation with simple dosing, low excipient cost, and a long in-use period could support limited procurement demand. A powder-for-reconstitution product may reduce shipping weight and improve shelf life compared with a ready-to-use liquid.

Tropical stability

A formulation designed for high-temperature and high-humidity regions may have value in countries where cold-chain infrastructure is limited. The opportunity is strongest if the product avoids specialized packaging or expensive moisture barriers.

Fixed-dose combinations

Stavudine has historically been used in combinations with lamivudine and nevirapine. A new fixed-dose product could reduce pill burden, but current treatment guidelines and toxicology concerns weaken demand. Any development would require careful assessment of country-specific treatment policy and procurement eligibility.

Contract manufacturing

The most realistic business model may be contract production for legacy markets rather than a branded formulation launch. The value proposition would be dependable supply, low minimum order quantities, and compliant manufacturing.

How does stavudine compare with other HIV drug opportunities?

Stavudine has a weaker commercial profile than modern antiretroviral active ingredients. Its low API cost and expired basic IP are advantages for public-sector supply, but they do not offset declining clinical use.

An excipient platform developed for stavudine could have greater value if designed for transfer to other pediatric or heat-sensitive products. Taste masking, dry suspension technology, low-moisture granulation, and dose-flexible multiparticulates are reusable capabilities. The platform, rather than stavudine itself, is the more defensible asset.

What is the outlook for stavudine patent litigation and Paragraph IV challenges?

Current Paragraph IV activity around the original Zerit product is unlikely to be commercially significant because the principal exclusivity period has ended and the product is no longer a major U.S. market opportunity. No meaningful current patent litigation or settlement framework is associated with routine generic entry.

A new formulation could generate patent disputes if it obtained U.S. approval and listed claims in the Orange Book. That scenario would require a commercially viable product with enforceable formulation claims. For conventional capsules using standard excipients, litigation risk is low because there is little remaining patent value to challenge.

Key Takeaways

• Stavudine is an obsolete or highly restricted HIV treatment in most modern guidelines.
• The original Zerit formulation used conventional capsule excipients and a preserved oral solution system.
• Legacy composition, formulation, and method-of-use exclusivity do not provide a meaningful current barrier.
• The strongest formulation opportunity is a low-cost pediatric powder or suspension with improved taste, redispersibility, and tropical stability.
• A conventional generic capsule is technically feasible but commercially dependent on localized legacy demand.
• Fixed-dose combinations face substantial clinical and procurement limitations.
• Biosimilar analysis is not applicable because stavudine is a small molecule.
• New patent value would need to come from measurable formulation performance, not routine excipient substitution.
• The most transferable asset is an excipient and manufacturing platform that can also support better-positioned pediatric medicines.

FAQs About Stavudine Excipients and Commercial Development

Is stavudine still used in HIV treatment?

It has limited residual use and is generally excluded from preferred modern regimens because of mitochondrial and metabolic toxicity.

Can a company launch a generic stavudine capsule without a new formulation patent?

Yes. A conventional product may rely on an abbreviated or national generic approval pathway, subject to applicable reference-product, bioequivalence, quality, and stability requirements.

What is the best dosage form for a new stavudine product?

A powder for oral solution or pediatric suspension offers more differentiation than a standard capsule, especially where flexible dosing and tropical stability are important.

Are stavudine liquid formulations commercially attractive?

Only in narrow markets. Their value depends on pediatric demand, procurement policy, acceptable toxicity management, and the ability to provide stable, palatable, accurately dosed medicine.

Could an excipient patent create a strong stavudine franchise?

A patent could provide moderate protection if it demonstrates an unexpected improvement in stability, taste, dose uniformity, or in-use performance. It would not create a strong franchise by itself because the underlying drug has limited clinical demand.

References

1. U.S. Food and Drug Administration. (2008). Zerit (stavudine) capsules and oral solution: Prescribing information. Bristol-Myers Squibb.

2. National Institutes of Health. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. ClinicalInfo.HIV.gov.

3. World Health Organization. (2021). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach. World Health Organization.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. U.S. Department of Health and Human Services.